(AMPH) Amphastar P - Ratings and Ratios

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a bio-pharmaceutical company specializing in the development, manufacturing, and distribution of generic and proprietary injectable, inhalation, and intranasal products. With operations in the United States, China, and France, the company focuses on critical care and emergency medicine, offering a diverse portfolio of products that address acute and life-threatening conditions. Its product lineup includes BAQSIMI, a nasal spray for severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for mild asthma symptoms; and Enoxaparin for deep vein thrombosis prevention and treatment. Additionally, Amphastar provides REXTOVY and Naloxone for opioid overdose reversal, Glucagon emergency kits, and Cortrosyn for diagnostic purposes in adrenocortical insufficiency screening.

The company also manufactures Amphadase, a hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly and topical solution for anesthetic use; Phytonadione injection for newborns; emergency syringe products; morphine injection for patient-controlled analgesia; and Lorazepam injection for surgical procedures. Its portfolio further includes Neostigmine methylsulfate for myasthenia gravis treatment; Isoproterenol hydrochloride for heart block episodes; Ganirelix Acetate for premature luteinizing hormone surge inhibition; Vasopressin for blood pressure management; and Regadenoson for myocardial perfusion imaging. Amphastar also distributes recombinant human insulin APIs and porcine insulin API, while developing generic and biosimilar product candidates, including intranasal epinephrine for allergic reactions.

Founded in 1996 and headquartered in Rancho Cucamonga, California, Amphastar has established itself as a key player in the pharmaceutical industry, particularly in injectable and inhalation technologies. The company’s focus on R&D and its extensive product range position it as a reliable supplier of essential medications for critical care and emergency situations.

Ticker Symbol: AMPH
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Pharmaceuticals

Average Volume 20d: 543,608
Last Price: 24.50
SMA 20: 24.17
SMA 50: 26.78
SMA 200: 38.99
ATR: 1.02

Market Cap: 1,136.73M USD
P/E: 7.82
P/E Forward: None
P/B: 1.55
P/S: 1.55
RoE: 21.78

Forecast: Based on the provided data, Amphastar Pharmaceuticals (AMPH) is currently trading at $24.50, slightly above its SMA 20 of $24.17 but below its SMA 50 of $26.78. The stock’s ATR of 1.02 indicates moderate volatility. Fundamentally, the company’s P/E ratio of 7.82 suggests undervaluation compared to industry peers, while its return on equity (RoE) of 21.78 highlights strong profitability. However, the P/S ratio of 1.55 may signal elevated valuations relative to sales. Moving forward, AMPH is likely to experience short-term price consolidation near the SMA 50 resistance level, with potential upside driven by its robust earnings and product pipeline. Investors should monitor technical support at the SMA 20 and fundamental catalysts such as new product approvals or margin expansion.